RIG-I是一个细胞内检查点,限制CD8+T细胞抗瘤免疫力
Xiaobing Duan1,2, Jiali Hu3, Yuncong Zhang3
1Guangdong Provincial Key Laboratory of Tumour Interventional Diagnosis and Treatment, Zhuhai People's Hospital (Zhuhai Clinical Medical College of Jinan University), Zhuhai, 519000, China. duanxb3@mail3.sysu.edu.cn.
网红酸诱导基因I (RIG-I) 作为细胞内检查点,抑制CD8+T细胞抗瘤免疫力. 准RIG-I可能会增强癌症免疫疗法反应.
科学领域:
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
- 分子生物学分子生物学
背景情况:
- 网红酸诱导基因I (RIG-I) 是一种模式识别受体,对先天免疫至关重要.
- 它在适应性免疫,特别是CD8+T细胞介导的抗瘤反应中的特定作用尚不清楚.
研究的目的:
- 为了研究RIG-I在CD8+T细胞抗瘤免疫中的功能.
- 确定RIG-I是否作为癌症免疫治疗的治疗标.
主要方法:
- 在瘤透的CD8+T细胞中RIG-I表达的分析.
- 研究RIG-I的下游信号通路,包括AKT/糖解.
- 在临床前瘤模型中评估RIG-I淘汰和抑制策略.
- 与PD-1阻断组合疗法的评估.
主要成果:
- 在瘤透的CD8+T细胞中,RIG-I被上调,从而对其功能产生负面调节.
- 激活的T细胞诱导RIG-I上调,并抑制AKT/糖解路径.
- RIG-I淘汰赛增强了收养转移的T细胞对固体瘤的疗效.
- RIG-I 抑制改善了对PD-1 阻断免疫疗法的反应.
结论:
- RIG-I作为一个细胞内检查点,限制CD8+T细胞抗瘤免疫力.
- 准RIG-I代表了增强癌症免疫疗法的有希望的策略,可能与免疫检查点抑制剂结合使用.
更多相关视频
10:13Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
Published on: May 6, 2019
12:43Monitoring Activation of the Antiviral Pattern Recognition Receptors RIG-I And PKR By Limited Protease Digestion and Native PAGE
Published on: July 29, 2014
相关概念视频
Inhibition of Cdk Activity
Experimental RNAi
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Tumor Immunotherapy
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
